BioNTech Just Proved mRNA Can Fight Cancer, Not Just COVID
BioNTech's mRNA cancer vaccine just hit its primary endpoint in advanced melanoma patients who'd already failed checkpoint immunotherapy. The response rates are modest, but in a field littered with failed cancer vaccines, even modest is a milestone.
A COVID Vaccine Maker Walks Into an Oncology Ward
Three years ago, if you told investors that BioNTech's mRNA technology would shrink tumors in patients who'd already failed the best immunotherapy drugs on the market, most would have laughed. COVID vaccines? Sure. But cancer?
Nobody's laughing now.
BioNTech just reported that its mRNA cancer vaccine, BNT111, combined with the checkpoint inhibitor cemiplimab (Regeneron's Libtayo), met its primary endpoint in a Phase 2 trial for advanced melanoma. The treatment posted an 18.1% overall response rate (ORR), which is the percentage of patients whose tumors meaningfully shrank. That might sound modest until you realize the historical benchmark for these patients is just 10%.
These are patients who had already tried and failed anti-PD-1 therapy, the current gold standard. They were essentially running out of options. And an off-the-shelf mRNA vaccine gave some of them a second chance.
The Toughest Crowd in Oncology
To appreciate what's happening here, you need to understand the patient population. These aren't newly diagnosed melanoma patients. They have unresectable stage III or IV disease, meaning surgery isn't an option. Worse, their cancer had already progressed on anti-PD-1 checkpoint inhibitors, the drugs that revolutionized melanoma treatment over the last decade.
Once you've failed a PD-1 inhibitor, the playbook gets thin. Retreating with another PD-1 drug typically yields response rates in the low-to-mid teens at best, with a median progression-free survival of just two to five months. Some patients try ipilimumab-based combinations, but those carry brutal side effects. Cell therapies like TIL (tumor-infiltrating lymphocytes) can work, but they're complex, expensive, and hard to scale.
Think of it like a restaurant with a very limited late-night menu. You'll eat what's available, but you won't be excited about it.
What BNT111 Actually Does
BNT111 isn't your typical vaccine. It doesn't prevent melanoma. Instead, it trains the immune system to recognize and attack cancer cells that are already there.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
The vaccine uses BioNTech's "FixVac" platform: mRNA packaged in RNA-lipoplex (RNA-LPX) formulation, injected intravenously, and designed to home in on dendritic cells (the immune system's intelligence officers). Once inside those cells, the mRNA instructs them to display four melanoma-associated proteins on their surface: NY-ESO-1, MAGE-A3, tyrosinase, and TPTE.
It's like handing the immune system four different mugshots and saying, "Find these guys." BioNTech says over 90% of melanomas express at least one of these targets, which makes the approach broadly applicable without needing to customize the vaccine for each patient.
The trial (BNT111-01) randomized patients into three groups: BNT111 plus cemiplimab, BNT111 alone, and cemiplimab alone. The combination arm was the headliner, but there was a plot twist.
The Surprise: Monotherapy Held Its Own
The combo arm's 18.1% ORR cleared the statistical bar, with a p-value of 0.0115 against the 10% historical control. Disease control (including patients whose tumors at least stopped growing) reached 55.3%.
But the monotherapy arm quietly stole the show. BNT111 alone showed meaningful clinical activity, with double-digit complete responses in PD-1-refractory melanoma.
Meanwhile, cemiplimab alone performed roughly in line with historical expectations for PD-1 rechallenge: nothing to write home about.
Median overall survival for the combination arm came in at approximately 20.7 months, a meaningful number for patients who've exhausted standard options. The safety profile was manageable too, mostly flu-like symptoms (fever, chills) consistent with immune activation. No alarming new signals.
Nice, But Is It Enough?
Let's be honest: an 18% response rate won't win any beauty contests in oncology. In first-line melanoma, PD-1 inhibitors alone can hit 30-45% ORR. Combination immunotherapy with nivolumab plus ipilimumab pushes past 55%.
But context matters enormously. This is a salvage setting, where patients have already failed the treatments that produce those impressive numbers. In that world, nearly one in five patients responding (and more than one in ten achieving a complete response) is genuinely meaningful. The treatment also has FDA Fast Track designation and Orphan Drug status, signaling regulatory interest in getting something to market for these patients.
For BioNTech's stock, the data is "incrementally positive" rather than transformational. Analysts view BNT111 as a proof-of-platform win that validates the company's broader mRNA oncology ambitions. It's not going to single-handedly justify BioNTech's market cap, but it answers an important question: can therapeutic mRNA vaccines actually shrink tumors in humans? The answer, clearly, is yes.
The Bigger Race: mRNA vs. Cancer
BioNTech isn't alone in this arena. Moderna and Merck have been making headlines with their personalized cancer vaccine, mRNA-4157 (V940), which encodes up to 34 patient-specific neoantigens. Their Phase 2b data in adjuvant melanoma showed a 49% reduction in the risk of cancer recurrence when combined with pembrolizumab, with benefits holding out to five years.
The key difference: Moderna/Merck's vaccine is personalized (custom-built for each patient's tumor mutations), while BioNTech's BNT111 is off-the-shelf (shared antigens, same product for every patient). Personalization may deliver stronger immune responses, but it adds manufacturing complexity, turnaround time, and cost. BNT111 trades some precision for scalability.
BioNTech is also pursuing the personalized route with autogene cevumeran (BNT122), its individualized neoantigen vaccine developed with Genentech. That program is being tested in colorectal cancer and other solid tumors, with interim data expected soon.
The company now plans to have 15 Phase 3 oncology trials running by the end of 2026, spanning mRNA vaccines, bispecific antibodies, and antibody-drug conjugates. Multiple late-stage readouts are expected in the coming years.
What This Really Means
Five years ago, the idea of injecting mRNA to treat cancer felt like science fiction to most people. COVID changed the public's relationship with mRNA technology. Now BioNTech is showing that the same molecular trick that taught our cells to recognize spike proteins can teach them to recognize tumors.
BNT111's results aren't a home run. They're more like a solid double that advances the runner. But in a field where cancer vaccines have disappointed for decades, even a double counts for a lot. The mRNA oncology era isn't coming; it's here. And the data, while modest, is real.
For the thousands of melanoma patients who've exhausted their options, "modest" might just be another word for "hope."
Clinical & Regulatory4 min read
The Underdog That Just Knocked Out a $13 Billion Giant
UCB's Bimzelx just beat AbbVie's Skyrizi in a head-to-head psoriatic arthritis trial, posting the first-ever biologic superiority win on a major joint endpoint. The results could reshape how doctors pick treatments in a $13 billion market.
